EX-99.1 2 ea190383ex99-1_inmedpharma.htm PRESS RELEASE, DATED DECEMBER 19, 2023

Exhibit 99.1 




Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com



InMed Announces Results of 2023 Annual General Meeting


Vancouver, BC – December 19, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 27, 2023, were approved by the shareholders. A total of 1,292,647 common shares of the Company, representing approximately 38.84% of the Company’s 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the Meeting. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:


   Votes For   Withheld Votes 
Director  Number   Percentage   Number   Percentage 
Eric A. Adams   160,711    76.09%   50,513    23.91%
Janet Grove   141,882    67.17%   69,342    32.83%
Andrew Hull   141,398    66.94%   69,826    33.06%
Nicole Lemerond   145,865    69.06%   65,359    30.94%
Bryan Baldasare   145,659    68.96%   65,565    31.04%


InMed filed a report of voting results on SEDAR at www.sedar.com on December 19, 2023.


About InMed:


InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.


Investor Contact:


Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com


Cautionary Note Regarding Forward-Looking Information:


This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.


All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.